Scholar Rock Phase 3 SAPPHIRE trial meets primary endpoint; Q3 net loss $64.5M

Scholar Rock Holding Corp

2024-Q3 EPS reported -$1.86

Phase 3 SAPPHIRE achieved primary endpoint: apitegromab 1.8-point HFMSE improvement (p=0.0192) vs placebo.
Plans to submit BLA and MAA for apitegromab in SMA in Q1 2025.
Phase 2 EMBRAZE trial (apitegromab + GLP-1 for obesity) fully enrolled; data expected Q2 2025.
Completed upsized $345M public offering; proforma cash $463.5M extends runway into Q4 2026.
Q3 2024 net loss $64.5M ($0.66/share) vs $42.4M ($0.53/share) in Q3 2023; no revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.